Staple Line Reinforcement for Intracorporeal Anastomosis Reduces Time for Reconstruction During Laparoscopic Gastrectomy for Gastric Cancer

Namikawa, Tsutomu; Utsunomiya, Masato; Yokota, Keiichiro; Munekage, Masaya; Uemura, Sunao; Maeda, Hiromichi; Kitagawa, Hiroyuki; Kobayashi, Mariko; Hanazaki, Kazuhiro; Seo, Satoru

doi:10.21873/anticanres.16147

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study of patients with head and neck cancer also found that taking lafutidine during S-1 treatment alleviated gastrointestinal toxicity. Namikawa et al also reported that the use of lafutidine together with S-1 reduced the incidence of diarrhoea, and the incidence of diarrhoea was similarly significantly reduced in the present study (6). The gastrointestinal mucosal-protective action is likely mediated by the capsaicin-sensitive sensory neurons identified in the basic experiments on rats described above (8).…”

Section: Discussionsupporting

confidence: 74%

“…One study of lafutidine use in patients receiving S-1 as adjuvant therapy after gastric cancer surgery reported a significant reduction in the incidence of adverse events such as gastroesophageal reflux and diarrhoea, and potentially enhancing the usefulness of S-1 (6). In light of that report, we considered that lafutidine might also reduce adverse events of S-1 in patients with head and neck cancer, and therefore conducted the present study to investigate this hypothesis.…”

Section: Discussionmentioning

confidence: 95%

“…The limitations of this study include its nature as a retrospective study at a single institution with limited sample size, and the possibility of variation in patient attributes. At our hospitals, we also follow the approach of Namikawa et al (6) in using mainly lafutidine as prophylaxis for S1induced gastrointestinal toxicity. We therefore excluded patients taking other types of gastrointestinal mucosalprotective medication because of their small numbers, and were unable to compare these medications with lafutidine.…”

Section: Discussionmentioning

confidence: 99%

“…with gastric cancer, the use of lafutidine together with S-1 as postoperative adjuvant chemotherapy significantly reduced the incidence of gastroesophageal reflux and diarrhoea as adverse events. The frequency of S-1 dose reduction or withdrawal was significantly lower in patients who also took lafutidine (30% vs. 83%, p=0.027), and its therapeutic effect may have been enhanced (6). Lafutidine is an H2 blocker.…”

mentioning

confidence: 94%

See 3 more Smart Citations

Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study

et al. 2021

View full text Add to dashboard Cite

Background/Aim: This study evaluated the utility of the histamine H2-receptor antagonist lafutidine in patients taking oral fluorouracil (S-1) for head and neck squamous cell carcinoma (HNSCC), by comparing patients with and without concomitant lafutidine. Patients and Methods: Study subjects comprised 63 patients who received adjuvant S-1 following curative resection of HNSCC at our institutions between August 1, 2013 and December 31, 2019. The primary endpoint was the completion rate of S-1 therapy. Results: For the lafutidine-treated group, the median completion rate was significantly greater (94.4% vs. 24.6%, p=0.01), and progression-free and overall survival were both significantly prolonged compared to the non-lafutidine group. In terms of adverse events, the incidence of diarrhoea was significantly reduced (p<0.00189) in the lafutidinetreated group. Conclusion: Taking lafutidine during S-1 treatment appeared to reduce gastrointestinal disturbance and increased the S-1 completion rate, improving both progression-free and overall survival as a result.Curative treatment for locally advanced head and neck cancer has conventionally involved a combination of surgery and radiotherapy (1). Because the head and neck region not only carries out functions that play crucial roles in daily life, but is also an important site cosmetically, recent years have seen attempts to use concurrent chemoradiotherapy as curative treatment, with the goal of sparing organs and their functions.In cases of advanced cancer, however, the prognosis cannot be considered satisfactory, even for patients who have undergone curative therapy, and adjuvant chemotherapy following curative treatment is reportedly useful (1, 2).Two large-scale Japanese studies of adjuvant chemotherapy for advanced head and neck cancer have been reported. The first, a comparative trial conducted by Tsukada et al., administered tegafur and uracil (UFT) to patients for 1 year following curative therapy for head and neck cancer (3). The study incIuded patients with I-IV primary squamous cell carcinoma of the head and neck with no distant metastasis. Although both the 3-year overall survival (OS) rate (UFT group, 77.9%; untreated group, 72.9%) and 3-year relapse-free survival rate (UFT group, 73.4%; untreated group, 66.2%) tended to be better in the UFT-treated group, the difference was not significant. The distant recurrence rate, however, was significantly lower in the UFT group (7.9% vs. 14.6%, respectively; p=0.034), suggesting that UFT is useful as adjuvant chemotherapy.The second large-scale study was the ACTS-HNC study by Tsukahara et al., as a comparative trial of S-1 and UFT (4). Both 3-year disease-free survival and 3-year relapse-free survival tended to be better in the S-1-treated group, and OS was significantly better (p=0.022). However, the incidence of mucositis/stomatitis as an adverse event was significantly higher in the S-1 group than in the UFT group. The 1-year completion rate for S-1 was low, at 43%, and control of adverse events was conjectured ...

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 94%

See 2 more Smart Citations